Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

8

Deferred tax assets, net 167,368 176,619

Other current assets 108,106 43,267

Total current assets 1,588,163 1,422,025

PROPERTY AND EQUIPMENT, net 501,575 500,396

GOODWILL 471,127 476,515

INTANGIBLE ASSETS, net 753,286 817,828

DEFERRED TAX ASSETS, net 171,865 141,752

OTHER ASSETS 169,589 147,753

$3,655,605 $3,506,269

CURRENT LIABILITIES:

Current portion of long-term debt $1,023,104 $1,237,169

Accounts payable 81,323 91,437

Accrued expenses 723,728 677,184

Total current liabilities 1,828,155 2,005,790

LONG-TERM DEBT 2,729 3,788

DEFERRED TAX LIABILITIES, net 72,088 56,540

OTHER LIABILITIES 180,539 138,084

Total liabilities 2,083,511 2,204,202

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 713 700

Additional paid-in capital 2,050,035 1,934,965

Treasury stock, at cost (194,782) (158,173)

Accumulated deficit (413,166) (624,128)

Accumulated other comprehensive

income 129,294 148,703

Total stockholders' equity 1,572,094 1,302,067

$3,655,605 $3,506,269
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Medarex, Inc.,(Nasdaq: MEDX ) announced today that it ... Emerging Growth Conference in New York City on Tuesday,September ... will be,webcast live and will be available for replay ... the Medarex website via the Internet at, http://www.medarex.com ...
... Leading scientists,from around the world will meet in ... producing life-saving vaccines and,antibodies. More than 125 scientists ... for New Vaccines II: Focus on Respiratory Virus,Diseases" ... The international,scientific workshop is being organized by the ...
... (Amex: PTN ) stated today that the ... Technologies, Inc. (Amex: CTT ),relating to a ... was,false and misleading. The press release issued ... with Palatin Technologies." However, the,Notice of Termination sent ...
Cached Biology Technology:International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development 2Palatin Technologies Refutes Competitive Technologies Contention of Material Breach 2
(Date:11/15/2014)... -- While we may still be a few years away from ... to gain instant access to all that ailed his patients, ... tablets for monitoring and measuring our health are cropping up ... a tad Orwellian to some, but a new survey suggests ... opportunities into their healthcare regime. These are some ...
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
(Date:11/7/2014)... Leading Biometric companies aim to provide ... online transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... BABA ), Google Inc. (NASDAQ: GOOG ), Microsoft ... EBAY ) and MasterCard Inc. (NYSE: MA) ... biometric authentication company focused on the growing mobile commerce is ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... of forests may have been the primary cause of the ... and cave lion, according to Durham University scientists. The ... beings were the primary cause of the extinction of mammals ... The research is part of the most comprehensive study ...
... assistant professor of biochemistry with the Fralin Life Science Institute ... the National Science Foundation (NSF) to advance his research on ... Iron is essential for all life. The level of ... and Mycobacterium tuberculosis need. To satisfy their ...
... Tricking honey bees into thinking they have traveled ... their brains, researchers report this month. Their study, in ... the first to identify distance-responsive genes. Foraging ... they communicate in a language humans can decode, said ...
Cached Biology News:Dwindling green pastures, not hunting, may have killed off the mammoth 2Dwindling green pastures, not hunting, may have killed off the mammoth 3Research targets basic metabolism of disease-causing fungi, bacteria 2Brain gene expression changes when honey bees go the distance 2
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... cassette is designed to allow ampicillin ... promoter gb2 driving the gene for ampicillin ... the Em7 promoter. It mediates higher transcription ... A synthetic polyadenylation signal terminates the ampicillin ...
... is designed for the fast and simple ... at any position (for the generation of ... is designed to allow neomycin / kanamycin ... combines a prokaryotic promoter (gb2) for expression ...
... Pyronin Y is most widely used ... selectively and differentially stain nucleic acids ... dichromatic dye solution, Pyronin Y stains ... DNA green. Chem comp: ...
Biology Products: